Publicly Listed Fusion Antibodies is a London Stock Exchange listed contract research organization with a Belfast base, signaling both formal governance and potential credibility leverage for partnerships, joint ventures, and large-scale collaborations with investors and pharma customers.

Clinical Milestones With hundreds of projects guided through preclinical stages and several advancing to clinical phases, there are multiple opportunities to upsell late-stage discovery, optimization, and developability services to sponsors transitioning from preclinical to Phase I–II trials.

Proprietary Platforms In-house platforms for Antibody Humanization, Affinity Maturation and Developability optimization (CRX, RAMP, ADD) present a clear cross-sell path to clients seeking end-to-end antibody development and risk-reduction before clinical testing.

Strategic Partnerships Recent collaborations and IP transfers, including partnerships with Finn Therapeutics and engagement with the National Cancer Institute, indicate a momentum to expand client network and secure funded projects, offering a door-to-door selling point for new collaborations.

Growth Signals Recent funding activity, new commercial services such as Mammalian Display, and expansions in follow-on projects point to growing demand for early-stage discovery and screening services, suggesting opportunities to propose expanded service scopes and long-term retainer-style engagements.